An Open Label, Randomized, Three-Period Crossover Study to Compare the Pharmacokinetic Profile of Paroxetine After Single Doses of the Controlled-Release Paroxetine Tablets at the Dose Levels of 12.5, 25 and 50mg in Healthy Japanese Male Subjects.

Trial Profile

An Open Label, Randomized, Three-Period Crossover Study to Compare the Pharmacokinetic Profile of Paroxetine After Single Doses of the Controlled-Release Paroxetine Tablets at the Dose Levels of 12.5, 25 and 50mg in Healthy Japanese Male Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jul 2017

At a glance

  • Drugs Paroxetine (Primary)
  • Indications Affective disorders; Anxiety disorders; Depressive disorders
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 02 Mar 2010 Actual patient number (18) added as reported by ClinicalTrials.gov.
    • 02 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Aug 2009 Trial location (Japan) identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top